Secondly, diagnosis of pancreatic cancer by peripheral blood-examination for anti-Survivin antibodies, as in lung or colorectal cancer (Rohayem et al, 2000) or analysis of pancreatic duct cytology samples, analogous to urine detection of Survivin as a diagnostic test for bladder cancer, (Smith et al, 2001) may be possible. This evidence concerns the gene BIRC5 and familial pancreatic carcinoma.